Recombinant Human Stathmin Protein，His

Stathmin, also known as oncoprotein 18, is a key regulator of microtubule dynamics, playing a crucial role in cell signaling, proliferation, and migration. Its dysregulation has been implicated in various cancers, making it an important target for therapeutic intervention. The protein interacts with tubulin, promoting microtubule depolymerization, thus influencing the cytoskeletal structure and cellular architecture. Given its significant role in cell cycle regulation and apoptosis, understanding the structural and functional properties of Stathmin is essential for elucidating its involvement in tumorigenesis. Researchers have focused on the recombinant production of Stathmin to study its biophysical characteristics and interactions with microtubules in detail. This approach allows for controlled experimental conditions and the ability to modify the protein for functional assays and potential drug development. The elucidation of Stathmin's structure through techniques like X-ray crystallography and nuclear magnetic resonance (NMR) has provided insights into its mechanism of action and identified potential inhibitors that could disrupt its function, presenting new avenues for cancer therapy. Moreover, the study of Stathmin's role in cellular processes may also inform on its function in normal physiological conditions, thereby deepening the understanding of cellular motility and division. As research progresses, Stathmin continues to be a focal point in the quest for novel cancer treatments, highlighting the intersection of basic science and therapeutic innovation.